Examining the Influence of Cardiovascular Outcome Trials: Is It the Heart of Diabetes?


To better understand type 2 diabetes management, you have to understand cardiovascular outcome trials (CVOTs). This interactive session will explore the unique properties, A1C-lowering effects, and CVOTs of dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, and sodium–glucose cotransporter 2 inhibitors. Using the data, participants will be able to better advise their patients on diabetes management and evaluate future CVOTs.

Pharmacist Learning Objectives

At the completion of this application-based activity, participants will be able to:

  1. Evaluate the potential benefits of antidiabetic drug therapy beyond A1C-lowering effects.
  2. Summarize the results of cardiovascular outcome trials (CVOTs) of antidiabetic drug therapy.
  3. Design an individualized evidence-based pharmacotherapeutic plan for a patient with type 2 diabetes.
  4. Recommend strategies for identifying and integrating into practice the results of new CVOT literature involving antidiabetic drug therapy.
Kristi Kelley, PharmD, BCPS, BCACP, CDE, BC-ADM
Clinical Professor
Auburn University Harrison School of Pharmacy
Melody Hartzler, PharmD, BCACP, BC-ADM
Melody Hartzler
Cedarville University School of Pharmacy
Learning Level: Level 3
Track: Pharmacist Clinical Patient Care Services, Ambulatory Care
Session Time Slot(s): 
Sunday, March 24
1:00 PM - 3:00 PM
Washington State Convention Center - Ballroom 6E
ACPE Pharmacist: 0202-0000-19-064-L01-P
CEUs Pharmacist: .2
Activity Type: